Skip to main content

Experiencing Agitation with Alzheimer’s Disease?

Explore Alzheimer’s-Related Agitation Clinical Trials Evaluating  Investigational Medications!

Alzheimer’s disease is the most common form of dementia. It is a neurodegenerative disorder that leads to morbidity and eventual mortality. Agitation in Alzheimer’s patients, aggression, hallucination, and delusions are estimated to affect 90% of people with Alzheimer’s disease, with an increasing prevalence as the disease progresses.

Although millions of people worldwide are affected, there remains a significant gap in research for innovative therapies that could assist those with Alzheimer’s experiencing agitation. Revive Research Institute is conducting paid Alzheimer’s-related Agitation Clinical Trials for agitation symptoms and investigating potential treatment options.

You may be eligible for the paid Agitation Associated with Alzheimer’s Dementia Clinical Study if you:

  • Are between 65 to 90 years of age
  • Have been diagnosed with Alzheimer’s disease
  • Have moderate to severe agitation for at least 2 weeks
  • Have a dedicated caregiver

*Additional criteria may apply

*Take part in paid Alzheimer’s-related Agitation Clinical Trials at no cost to you or your private medical insurance. You will be reimbursed financially for your time and travel. In addition, all participants receive study-related care from an experienced research team.

*If you or a family member is interested in participating in the Alzheimer’s-related Agitation Clinical Trials or would like more information, please fill out the form so we can determine if you qualify for the study and can contact you. Note that this is an entirely voluntary decision.

Please provide YOUR contact information only.
For more info, please visit Privacy Policy.
Alzheimers Related Agitation Clinical Trials

About the Alzheimer’s-Related Agitation Clinical Trials

Alzheimer’s disease is a chronic neurodegenerative disorder affecting around 5.8 million Americans. We are conducting Alzheimer’s-related Agitation Clinical Trials to assess the safety and efficacy of investigational medication in adult (65 to 90 years old) males and females with Alzheimer’s disease and agitation symptoms. Participants in this paid Agitation Associated with Alzheimer’s Dementia Clinical Study will be given the study treatment or a placebo.

Alzheimer’s-related Agitation Clinical Trials will take place at various locations throughout the United States. This is a multicentered, randomized, double-blind, placebo-controlled, phase III study.

The Agitation Associated with Alzheimer’s Dementia Clinical Study treatment for participants will last approximately 5 weeks. To ensure study eligibility, all participants must comply with all study procedures. Participants who meet the eligibility criteria and are chosen to participate will be given 5 weeks of double-blind active treatment or a placebo. We’re looking into the safety and efficacy of an oral investigational drug to treat agitation in Alzheimer’s patients.

*There is no cost to you, your private medical insurance, or the public health insurance plan for study procedures. The study drug, related procedures, and visits will be provided at no charge for the duration of the Agitation Associated with Alzheimer’s Dementia Clinical Study.

Get Started: What to Expect?

If you or someone you know is suffering from Alzheimer’s disease and would like to participate in our paid Alzheimer’s-Related Agitation Clinical Trials, please reach out to us by filling out the form above. One of our study team representatives will call you to see if you are a fit for this study as part of our screening process.

If you fulfill the initial screening criteria, you may be asked to visit the Agitation Associated with Alzheimer’s Dementia Clinical Study site. Our research team will discuss in detail with you the clinical during the Informed Consent process. After that, you will undergo a series of health-related questions and tests to confirm your eligibility as a participant.

Once you receive confirmation of eligibility, you will formally be a part of the Alzheimer’s-Related Agitation Clinical Trials. You will receive all the information about the research study you might enroll in during the ICF process. We encourage you to ask as many questions as you would like before deciding to participate.

*All study-related care is provided free of cost. Complete physical examination and other study-related assessments will be done by expert physicians and health care experts.

Length of study Treatment

5 weeks

Number of study visits

6 Visits



Agitation Due To Alzheimer's Disease: Delving into the "Why"

Alzheimer's-Related Agitation Clinical Trials

Alzheimer’s disease is a progressive brain disorder characterized by cognitive decline, memory loss, and impaired performance of daily activities.

Symptoms of Alzheimer’s disease

Symptoms of Alzheimer’s disease can be divided into early, middle-stage, and late symptoms. Neuropsychiatric symptoms include agitation in Alzheimer’s patients, aggression, depression, apathy, anxiety, delusions, and hallucinations. Out of these, agitation in Alzheimer’s patients symptoms are the most common and challenging issue.

Causes of Alzheimer’s disease

Alzheimer’s disease is believed to be a result of abnormal build-up of proteins in and around brain cells. One of these proteins is called amyloid. Amyloid deposits form plaques around the cells of the nervous system. Another protein called the tau protein also deposits and form tangles within brain cells in people with Alzheimer’s disease.

Frequently Asked Questions (FAQs)

1. How is Alzheimer's disease diagnosed?

To diagnose Alzheimer’s, physicians may use medical history, mental status tests, physical and neurological exams, diagnostic tests and brain imaging.

2. Do I have to pay to participate in Agitation Associated with Alzheimer’s Dementia Clinical Study?

Participation in Alzheimer’s-Related Agitation Clinical Trials is free of cost to both you and your private health insurance. If you qualify and decide to participate, you will be financially compensated for your time and travel. Details of the stipend will be given to you once you complete the screening process and move on to the informed consent process.

3. How common is Alzheimer's disease?

Alzheimer’s disease is the most common type of dementia (with agitation in Alzheimer’s patients). Current estimates are that about 5.8 million people in the United States have Alzheimer’s disease and related dementias.

4. What is the main cause of Alzheimer's?

Age is the single most significant factor. The likelihood of developing Alzheimer’s disease doubles every 5 years after you reach 65.

5. What are the 5 warning signs of Alzheimer's disease?

  • Memory loss that disrupts daily life.
  • Poor judgment, leading to bad decisions.
  • Losing track of dates or knowing current location.
  • Taking longer to complete normal daily tasks.
  • Repeating questions or forgetting recently learned information.
Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI

T: 248-564-1485